Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.
Bucki. Robert R; Namiot. Dorota B DB; Namiot. Zbigniew Z; Savage. Paul B PB; Janmey. Paul A PA
Key Findings
- LL-37 and WLBU2 bind to salivary mucins, especially via sialic acid residues.
- This binding reduces their antibacterial killing power in lab tests.
- CSA-13’s antibacterial activity is largely unaffected by the presence of mucins or whole saliva.
Practical Outcomes
- If you plan to use LL-37 or similar peptides for oral or throat health, expect their effectiveness to be dampened by saliva. Consider delivery methods that bypass the mouth (e.g., nasal sprays, topical skin applications) or use alternative agents like CSA-13 that are resistant to mucin inhibition. This insight helps refine dosing strategies and choice of antimicrobial compounds for self‑experimentation.
Summary
The study found that the natural antimicrobial peptide LL-37 (and its synthetic copy WLBU2) gets stuck to the sticky proteins (mucins) in saliva, which blocks their ability to kill bacteria. A different antimicrobial molecule, the cationic steroid CSA-13, keeps working even when mixed with the same amount of saliva.
Abstract
Cationic antimicrobial peptides (CAPs) are the effector molecules of innate immunity, similar in potency to classic antibiotics that function in the first-line of defence against infectious agents. The purpose of this study was to investigate the effects of negatively charged mucins on the antibacterial activity of the positively charged cathelicidin LL-37 peptide, its synthetic analogue WLBU2 and the antimicrobial cationic steroid CSA-13. Mucin, DNA, F-actin and hCAP-18/LL-37 in saliva samples were evaluated by microscopy or immunoblotting. Bacterial killing assays and determination of MICs were used to determine bactericidal activity. Binding of rhodamine-B-labelled LL-37 peptide to mucin was fluorimetrically assessed. Microscopic evaluation of saliva after addition of rhodamine-B-labelled LL-37 showed localization similar to that observed after the addition of a specific mucin-binding lectin. Immunoblotting confirmed the presence of hCAP-18/LL-37 in saliva samples and LL-37 peptide bound to isolated submaxillary gland mucin-coated plates. Mucin/LL-37 binding was partially prevented by treatment of mucin with neuraminidase, indicating involvement of sialic acid moieties. Decreased LL-37 and WLBU2 antibacterial activity was observed in the presence of mucin or dialysed human saliva, whereas CSA-13 antibacterial activity was significantly resistant to inhibition by mucins. This study shows that the antibacterial LL-37 peptide and its synthetic analogue WLBU2 are inhibited by salivary mucin and that the cationic steroid CSA-13 retains most of its function in the presence of an equal amount of mucin or saliva.
Study Information
pubmed
2008
2008-05-01T00:00:00.000Z
10.1093/jac/dkn176
75
51